KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Preferred Dividend Payments (2018 - 2022)

Xenon Pharmaceuticals (XENE) has disclosed Preferred Dividend Payments for 7 consecutive years, with $17000.0 as the latest value for Q4 2022.

  • Quarterly Preferred Dividend Payments fell 96.51% to $17000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$368000.0 through Dec 2022, down 120.52% year-over-year, with the annual reading at $437000.0 for FY2022, 75.65% down from the prior year.
  • Preferred Dividend Payments for Q4 2022 was $17000.0 at Xenon Pharmaceuticals, up from -$684000.0 in the prior quarter.
  • The five-year high for Preferred Dividend Payments was $1.6 million in Q3 2018, with the low at -$684000.0 in Q2 2022.
  • Average Preferred Dividend Payments over 5 years is $376500.0, with a median of $356000.0 recorded in 2020.
  • The sharpest move saw Preferred Dividend Payments soared 10320.0% in 2021, then tumbled 231.29% in 2022.
  • Over 5 years, Preferred Dividend Payments stood at $1.6 million in 2018, then tumbled by 73.97% to $422000.0 in 2019, then fell by 17.06% to $350000.0 in 2020, then surged by 39.14% to $487000.0 in 2021, then plummeted by 96.51% to $17000.0 in 2022.
  • According to Business Quant data, Preferred Dividend Payments over the past three periods came in at $17000.0, -$684000.0, and $299000.0 for Q4 2022, Q2 2022, and Q1 2022 respectively.